Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Visual pathway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Visual pathway. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-003030-14 Sponsor Protocol Number: 758/11 Start Date*: 2012-09-03
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Nerve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas.
    Medical condition: Glioma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030953 Optic tract glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005264-60 Sponsor Protocol Number: CHF6467-OPG Start Date*: 2021-11-26
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT)
    Medical condition: Optic pathway glioma - optic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073338 Optic glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005786-14 Sponsor Protocol Number: 7830 Start Date*: 2021-10-13
    Sponsor Name:Hôpitaux Universitaires de Strasbourg B.1.2
    Full Title: A randomized and controlled phase II national protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a wild type BRAF gene newly diagnosed comparing a daily oral MEK i...
    Medical condition: Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002635-41 Sponsor Protocol Number: 15HI53 Start Date*: 2018-09-26
    Sponsor Name:Great Ormond Street Hospital
    Full Title: A paediatric phase I/II study of intermittent dosing of the MEK-1 inhibitor selumetinib in children with neurofibromatosis type-1 and inoperable plexiform neurofibroma and/or progressive optic path...
    Medical condition: Neurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    20.0 100000004864 10065866 Plexiform neurofibroma LLT
    20.0 100000004864 10030935 Optic nerve glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000519-18 Sponsor Protocol Number: P160906J Start Date*: 2019-04-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease
    Medical condition: Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10062249 Skin inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004395-11 Sponsor Protocol Number: MA/GH Start Date*: 2012-06-14
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: PHASE I/II CLINICAL TRIAL ON THE USE OF THE AMNIOTIC MEMBRANE FOR LARGE WOUND EPITHELIZATION
    Medical condition: extensive wounds
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10062932 Wound treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001198-22 Sponsor Protocol Number: ALXN2040-GA-201 Start Date*: 2021-12-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006270-15 Sponsor Protocol Number: CAFQ056A2206 Start Date*: 2009-03-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Pa...
    Medical condition: L-dopa induced dyskinesias in Parkinson’s patients with severe motor complications
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001343-55 Sponsor Protocol Number: A6061030 Start Date*: 2006-08-02
    Sponsor Name:Pfizer, S.A.
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).
    Medical condition: Postherpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029223 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003587-36 Sponsor Protocol Number: 684/MODREC/15 Start Date*: 2016-04-13
    Sponsor Name:Directorate of Defence Rehabilitation
    Full Title: Chronic Tendinopathy: The Biomechanical Associations and EfFicacy of Injectable Therapy (BE FIT) Study
    Medical condition: Chronic degenerative Achilles and patella tendinopathy patients, with neovascularisation on USS, who have failed best practice rehabilitation including Eccentric Loading (EL), Heavy Slow Resistance...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10000433 Achilles tendinitis LLT
    18.1 100000004859 10034123 Patellar tendinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001219-22 Sponsor Protocol Number: PGL11-021 Start Date*: 2012-06-11
    Sponsor Name:PregLem S.A.
    Full Title: A Phase IIa study investigating the efficacy and safety of the c-Jun-N-Terminal Kinase (JNK) inhibitor PGL5001 versus placebo administered for up to 5 months with concomitant administration of depo...
    Medical condition: Peritoneal and/or ovarian endometriosis with an inflammatory component.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10014784 Endometriosis of ovary LLT
    14.1 100000004872 10014785 Endometriosis of pelvic peritoneum LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002613-17 Sponsor Protocol Number: SONIBEC Start Date*: 2020-10-13
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (BCC) – ...
    Medical condition: Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors as defined by RECIST 1.1 and dermoscopic exam regardles...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003005-10 Sponsor Protocol Number: IGR2012/1883 Start Date*: 2013-06-06
    Sponsor Name:Gustave Roussy
    Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
    Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005112-42 Sponsor Protocol Number: C14-62 Start Date*: 2015-06-22
    Sponsor Name:INSERM
    Full Title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002802-21 Sponsor Protocol Number: PRIMERA001 Start Date*: 2020-12-18
    Sponsor Name:Erasmus Medical Center
    Full Title: PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, single-blinded, randomized controlled trial comparing usual care with a tailor-made approach
    Medical condition: Rheumatoid arthritis according to 2010 criteria
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10040107 Seropositive rheumatoid arthritis LLT
    23.1 100000004859 10062719 Seronegative rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003730-25 Sponsor Protocol Number: SBT20-102 Start Date*: 2017-02-14
    Sponsor Name:Stealth Bio Therapeutics Inc
    Full Title: A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease.
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005390-36 Sponsor Protocol Number: UoL001109 Start Date*: 2016-02-17
    Sponsor Name:The University of Liverpool
    Full Title: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a str...
    Medical condition: Behcets Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 03:34:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA